It's been a rollercoaster for the CSL (ASX:CSL) share price over the last 6 months

CSL shares have been on the volatility train lately. Here's the details.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's been a bumpy ride for CSL Limited (ASX: CSL) shareholders this past 6 months.

For those who can't stomach extreme volatility, CSL shares wouldn't have been an appropriate choice over the last half year.

Nonetheless, CSL shareholders have been rewarded with a 10% return for holding in this time – almost double the S&P/ASX 200 index (ASX: XJO)'s gain of 5.7%.

Let's take a closer look at the trek CSL shares have been on lately.

Scared looking people on a rollercoaster ride representing volatility.

Image source: Getty Images

How has the CSL share price performed this past 6 months?

All in all, CSL shares have climbed $27 per share since April and now trade at $290, after sailing through choppy waters.

After rallying from $263 to $305 in months from April to June, a broker downgrade out of investment bank giant Citibank appears to have plagued the biotechnology company's share price at that point.

It fell sharply from the peak in June to a low of $275 by the following month. It popped again in mid-July after it appointed a new non-executive director, and then again in August after the release of its FY21 results.

In its earnings report, the company outperformed on guidance. It grew revenue 10% year on year to $10 billion and net profit by 10% as well to $2.3 billion – well above guidance of 3% to 8% growth.

CSL shares have been on the move since this event, nearly reaching their 52-week high by the end of September.

However, the CSL share price has taken a step backwards since then, in line with a selloff in the broader markets.

For instance, CSL shares have given away 7% this past month, whereas, at last check, the S&P/ASX 200 Health Care index (XHJ) has also slipped over 6% in this time.

Most of this has occurred in the last few weeks, where CSL shares have slipped over 7% since 23 September, in line with the broad index.

In light of this, it's clear to see that it's been a bumpy ride for CSL shareholders this past 6 months, with big swings in the value of their holdings.

Zooming out the CSL share price

Taking a longer-term view, the situation appears very much the same. The CSL share price has gained 2.4% this year to date, and 1.9% over the last 12 months.

Looking at its chart, however, over this time, there are big swings in price and a wide 12-month range of $316.68 to $246.

After rallying over the past 2 months, CSL's share price has cooled off lately and currently trades at its July 2021 levels of $290.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Orthocell caps 26% surge this week with first US Military Surgery

The company's commercial rollout is off to a good start.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX health tech stock just hit a new record high. Could it go even higher?

Morgans believes there's still upside to be had.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Down almost 20% this year, how high could Mesoblast shares go?

The forward pipeline is looking promising.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares?

These three stocks might be too cheap to ignore.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Healthcare Shares

How much would $10,000 become if CSL shares returned to their record high?

After a sharp decline, CSL is in a new phase. The question is what happens next.

Read more »

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »